Search
Proteomics managing director Richard Lipscombe.

WA science firm in China deal

Nedlands company Proteomics International Laboratories is hoping for increased support for its initial public offering after finalising an agreement with a Chinese drug development business.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Sign up for free emails

Complete your details below to receive our twice-daily news emails and our BN Weekender.

CAPTCHA
Thanks! This question prevents spammers...
Image CAPTCHA
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/01/18

1 year TSR5 year TSR
270thProteomics International Laboratories34%0%
272ndDubber Corporation34%4%
332ndConnected IO22%48%
594thrent.com.au-23%-56%
712thOBJ-43%17%
709 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

12/09/17
$13k Bought
30/12/16
$3k Bought
28/12/16
$12k Bought
Total value as at the date of the transaction
Source: Morningstar

Revenue

128th↑Dubber Corporation$1.9m
129th↑Connected IO$1.9m
130th↓Proteomics International Laboratories$1.8m
131st↓OBJ$1.8m
132nd↑rent.com.au$1.7m
234 listed industrial companies ranked by revenue.
Source: Morningstar

Remuneration from Proteomics International Laboratories

409thRichard Lipscombe$325k
1191stJohn Dunlop$67k
1276thTerry Sweet$55k
Ranked by total remuneration from all listed WA companies

BNiQ Disclaimer